Definium’s LSD formula produces ‘best data ever seen’ in a pivotal depression trial, CEO says — Live Feedhttps://www.live-feeds.com/feed/definium-s-lsd-formula-produces-best-data-ever-seen-in-a-pivotal-depression-trial-ceo-saysContinuously updated, source-cited coverage. Definium Reports Positive Phase 3 Results for LSD-Based Depression Drug DT120https://www.live-feeds.com/feed/definium-s-lsd-formula-produces-best-data-ever-seen-in-a-pivotal-depression-trial-ceo-sayshttps://www.live-feeds.com/feed/definium-s-lsd-formula-produces-best-data-ever-seen-in-a-pivotal-depression-trial-ceo-says#u14133Fri, 26 Jun 2026 09:37:04 +0000Definium Therapeutics announced that its DT120 orally disintegrating tablet met all primary and key secondary endpoints in the Phase 3 Emerge study for major depressive disorder. CEO Daniel Hang F. Barrow described the results as the "best data ever seen" in a pivotal depression trial. The company is currently awaiting data from a second pivotal trial.What's confirmed:The Phase 3 Emerge study of DT120 ODT met its primary endpoint with an 8.1 point placebo-adjusted improvement on the Montgomery-Åsberg Depression Rating Scale at week 6.DT120 ODT met all key secondary endpoints, includi